Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection

The Journal of Antimicrobial Chemotherapy
P K RussellR W Titball

Abstract

The efficacies of ciprofloxacin and doxycycline prophylaxis and therapy were assessed against experimental pneumonic plague infections induced by two strains of Yersinia pestis in a mouse model. When exposed to an aerosol of Y. pestis strain GB, containing 8.39 x 10(5) +/- 4.17 x 10(4) cfu, the retained dose was 7.3 x 10(3) +/- 2.3 x 10(3) cfu. When exposed to an aerosol of Y. pestis strain CO-92, containing 1.86 x 10(5) +/- 7.4 x 10(3) cfu, the retained dose was 3.4 x 10(4) +/- 2.6 x 10(3) cfu. Both strains resulted in a respiratory and systemic infection closely resembling human pneumonic plague. Ciprofloxacin prophylaxis and therapy was successful against both strains for up to 24 h after challenge, but not after 48 h. Both doxycycline prophylaxis and therapy regimens were ineffective against both strains, although strain CO-92 was more susceptible in vitro to doxycycline than strain GB and supra-MIC levels were achieved in the serum and lungs of the animal.

Citations

Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN Infectious Diseases Society of America
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L Lucy BoulangerGregory Mertz
Jun 2, 2011·Antimicrobial Agents and Chemotherapy·Jered M WendteKenneth D Clinkenbeard
Jan 4, 2013·PloS One·Nadine LemaîtreFlorent Sebbane
Jun 29, 2011·Future Microbiology·Mitali Sarkar-Tyson, Helen S Atkins
Feb 25, 2003·Journal of the American Veterinary Medical Association·Kathleen A Orloski, Sarah L Lathrop
Jun 10, 2006·Infectious Disease Clinics of North America·Janak Koirala
Nov 24, 2004·International Journal of Antimicrobial Agents·J StewardT J G Brooks
Sep 9, 2006·FEMS Microbiology Letters·Jingfu QiuRuifu Yang
Aug 29, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E Navas
Aug 29, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·B A Cunha
Jul 8, 2014·Cancer Treatment Reviews·Emilia MontagnaMarco Colleoni
Dec 24, 2013·Cancer Treatment Reviews·Gabriel Limaverde-SousaCarlos Gil Ferreira
Jul 25, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K LienU Emmenegger
Nov 8, 2017·Antimicrobial Agents and Chemotherapy·Jourdan A AnderssonAshok K Chopra
Apr 14, 2016·Antimicrobial Agents and Chemotherapy·Jourdan A AnderssonAshok K Chopra
Dec 9, 2004·Journal of Medical Microbiology·Michelle NelsonRichard W Titball
Oct 13, 2006·Journal of Medical Microbiology·Andrey P Anisimov, Kingsley K Amoako
Feb 16, 2006·Journal of Medical Microbiology·Richard Thomas, Tim Brooks
Aug 30, 2002·Postgraduate Medicine·Jeffrey A TjadenGregory J Martin
Feb 3, 2005·FEMS Microbiology Letters·Jingfu QiuRuifu Yang
Nov 2, 2017·Frontiers in Cellular and Infection Microbiology·Jourdan A AnderssonAshok K Chopra
Jun 3, 2021·Biomolecules·Florent Sebbane, Nadine Lemaître

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.